1061.HK

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

Retrieved on: 
星期四, 十月 13, 2022
Vance DeGeneres, Neurodegeneration, Anti-inflammatory, Hospital, Inflammation, Invention, VISTA, DED, Agreement, Eye, Glaucoma, Trial of the century, Product, Company, Leber's hereditary optic neuropathy, LHON, The Group, Mitochondrion, Group, Board, Duane syndrome, Patent, Oxidative stress, FDA, TRIPS Agreement, AMD, Pharmaceutical industry, Ophthalmology, SkQ, Dermatology

Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders.

Key Points: 
  • Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders.
  • The core technology behind Mitotech products is based on a novel class of small molecules - mitochondria targeting cardiolipin peroxidation inhibitors.
  • Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.
  • Additionally, glaucoma, Leber's Hereditary Optic Neuropathy (LHON), dry AMD, and uveitis programmes for SkQ1 ophthalmic solution are at pre-clinical stage.

Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022"

Retrieved on: 
星期二, 八月 16, 2022
Antibody, Growth, Hospital, Group, Forbes, Company, Wound healing, Solution, Dermatology, Ophthalmology

Only 200 companies were selected out of 20,000 publicly traded companies (with annual sales of between $10 million and $1 billion) in the Asia-Pacific region.

Key Points: 
  • Only 200 companies were selected out of 20,000 publicly traded companies (with annual sales of between $10 million and $1 billion) in the Asia-Pacific region.
  • The 200 companies were carefully picked based on Forbes' List Methodology ^ of quantitative criteria and qualitative screens.
  • EssexBio would like to extend its gratitude to all stakeholders for their contributions.
  • Essex Bio-Technology Limited is a biopharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic b-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998.

Essex Bio-Technology Announces 2021 Financial Results

Retrieved on: 
星期二, 三月 22, 2022
Conditional sentence, Hospital, SkQ, NMPA, US, Exudate, VISTA, Therapeutic Goods Administration, Trust, Trial of the century, Association of British HealthTech Industries, Cornea, Science, The Group, Therapy, DNA, Patent, Investment, Growth, Clinical trial, European Medicines Agency, Board, Board on Science, Technology, and Economic Policy, Review, Duane syndrome, COVID, Patient, IP, Company, Growth factor, Leadership, Group, Granule, City, US FDA, Oxidative stress, Czech Republic, MAH, COVID-19, Traction, Bevacizumab, Acquisition, Property management, Vaccine, Pharmaceutical industry, Television, Animal, Cosmetics, Renewable energy, Surgery, Dermatology, PRC, Ophthalmology

HONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.

Key Points: 
  • HONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.
  • Essex achieved significant progression and encouraging performances amid the COVID-19 pandemic and macro uncertainties.
  • Mr. Patrick Ngiam, Chairman of Essex, said, "2021 has been a year full of diverse challenges.
  • The Group has achieved significantly improved financial performances in the financial year ended 31 December 2021.